AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8963030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg qhs (R1)
Number of subjects: 6
Study 8963030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg bid (N2)
Number of subjects: 6
Study 8963030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg qhs (N1)
Number of subjects: 6
Study 8963030 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 6
Study 1949222 — intervention group
Group type: EXPERIMENTAL
Intervention: 6M regimen (28 weeks)
Number of subjects: 2218
Study 1949222 — intervention group
Group type: EXPERIMENTAL
Intervention: 8M regimen (36 weeks)
Number of subjects: 2218
Study 1949222 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 2218
Study 7450412 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 16,16-dimethyl PGE2 at doses of 0.01 to 0.1 microgram/kg
Number of subjects: 11
Study 7450412 — intervention group
Group type: COMPARATOR
Intervention: Oral 16,16-dimethyl PGE2 at doses of 0.01 to 1.0 microgram/kg
Number of subjects: 11
Study 7450412 — intervention group
Group type: COMPARATOR
Intervention: Oral 16,16-dimethyl PGE2 at 1 microgram/kg
Number of subjects: 11
Study 7450412 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 16,16-dimethyl PGE2 at 0.1 microgram/kg
Number of subjects: 11
Study 31785009 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% of maximal voluntary contraction (MVC)
Number of subjects: 15
Study 31785009 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% of maximal voluntary contraction (MVC)
Number of subjects: 15
Study 31785009 — intervention group
Group type: COMPARATOR
Intervention: 0% (control session)
Number of subjects: 15
Study 31785009 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained BB
Number of subjects: 15
Study 31785009 — intervention group
Group type: EXPERIMENTAL
Intervention: SICI, SP, and ICF in either BB
Number of subjects: 15
Study 30907817 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (10,000 IU/day)
Number of subjects: 88
Study 30907817 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose heparin (starting at 15,000 IU/day, adjusted to achieve an activated partial thromboplastin time of 1.5 to 2.5 times the baseline)
Number of subjects: 88
Study 30907817 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin groups (low and high dose combined)
Number of subjects: 88
Study 30907817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin dose)
Number of subjects: 88
Study 29275371 — intervention group
Group type: EXPERIMENTAL
Intervention: Different dual antiplatelet therapy durations and stent types
Number of subjects: 2003
Study 25659773 — intervention group
Group type: EXPERIMENTAL
Intervention: ELAPE
Number of subjects: 69
Study 25659773 — intervention group
Group type: COMPARATOR
Intervention: Conventional APE
Number of subjects: 69
Study 25402757 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA screening
Number of subjects: 900
Study 25402757 — intervention group
Group type: COMPARATOR
Intervention: Standard national guidelines-based optimal diabetes care
Number of subjects: 900
Study 22866292 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg quick-release lornoxicam (LNX)
Number of subjects: 83
Study 22866292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 19124815 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use at randomization (n = 397) for a median duration of at least 900 days over a median follow-up of 3.5 years.
Number of subjects: 1037
Study 17474817 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI add-on therapy (sertraline, citalopram, paroxetine, fluoxetine, fluvoxamine)
Number of subjects: 393
Study 17474817 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI add-on therapy (for chronic patients)
Number of subjects: 393
Study 16138575 — intervention group
Group type: EXPERIMENTAL
Intervention: Spraying the long‐acting antibacterial material JUS on the surface of catheter and urethral orifice
Number of subjects: 60
Study 16138575 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment of urethral orifice twice a day
Number of subjects: 60
Study 11192336 — intervention group
Group type: COMPARATOR
Intervention: Placebo with clinical management
Number of subjects: 307
Study 11192336 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant
Number of subjects: 307
Study 11192336 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem‐Solving Treatment
Number of subjects: 307
Study 9473217 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydroxyurea (80 mg/kg every 3 days)
Number of subjects: 29
Study 9473217 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydroxyurea (2000 mg as a 30-minute infusion)
Number of subjects: 29
Study 9473217 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intravenous hydroxyurea
Number of subjects: 29
Study 7827633 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial training on the Impulse system, three times per week for 5 weeks, focusing on the nondominant arm.
Number of subjects: 40
Study 7827633 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 40
Study 3151068 — intervention group
Group type: COMPARATOR
Intervention: GnRH withdrawal (Group A)
Number of subjects: 8
Study 3151068 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly GnRH pulses (Group B)
Number of subjects: 8
Study 30395821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient‐controlled analgesia (PCA)
Number of subjects: 40
Study 30395821 — intervention group
Group type: COMPARATOR
Intervention: Scheduled and as‐needed oral analgesia (non-PCA)
Number of subjects: 40
Study 28392393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve sparing prostatectomy augmented with seminal vesicle sparing
Number of subjects: 140
Study 28392393 — intervention group
Group type: COMPARATOR
Intervention: Standard nerve sparing prostatectomy
Number of subjects: 140
Study 26043913 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT), electrical stimulation (ES) and biofeedback
Number of subjects: 62
Study 26043913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT), electrical stimulation (ES), biofeedback plus 1 mg intravaginal estriol (IE)
Number of subjects: 62
Study 23520222 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment with the Short Term Assessment of Risk and Treatability (START) and shared care planning protocol
Number of subjects: 632
Study 23520222 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 632
Study 20795821 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk tools for preeclampsia
Number of subjects: 1687
Study 20795821 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model incorporating clinical risk factors
Number of subjects: 1687
Study 19349323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 78
Study 19349323 — intervention group
Group type: COMPARATOR
Intervention: Metformin (2000 mg/d)
Number of subjects: 78
Study 19349323 — intervention group
Group type: COMPARATOR
Intervention: Both therapies
Number of subjects: 78
Study 19349323 — intervention group
Group type: COMPARATOR
Intervention: Neither treatment
Number of subjects: 78
Study 16625988 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 25 mg under fasting condition (reference)
Number of subjects: 16
Study 16625988 — intervention group
Group type: COMPARATOR
Intervention: Almotriptan 25 mg under fed condition
Number of subjects: 16
Study 16625988 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 25 mg under fasting and fed conditions
Number of subjects: 16
Study 16625988 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 25 mg
Number of subjects: 16
Study 14604605 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 microg/kg clonidine i.v.
Number of subjects: 82
Study 14604605 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychiatric illness)
Number of subjects: 82
Study 14604605 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD with co-morbid depression
Number of subjects: 82
Study 10870871 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 50mg p.o. b.i.d.
Number of subjects: 214
Study 10870871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 8623859 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal electrocardiogram plus electronic fetal monitoring
Number of subjects: 214
Study 8623859 — intervention group
Group type: COMPARATOR
Intervention: Electronic fetal monitoring alone
Number of subjects: 214
Study 1582275 — intervention group
Group type: EXPERIMENTAL
Intervention: MESAM 4
Number of subjects: 56
Study 1582275 — intervention group
Group type: EXPERIMENTAL
Intervention: HVI (Heart Rate Variability Index)
Number of subjects: 56
Study 1582275 — intervention group
Group type: EXPERIMENTAL
Intervention: ISI (Snoring Index)
Number of subjects: 56
Study 1582275 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ODI, HVI, ISI
Number of subjects: 56
Study 1582275 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 56
Study 2414580 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 3 mg infused over 1 h
Number of subjects: 6
Study 2414580 — intervention group
Group type: COMPARATOR
Intervention: Idazoxan 0.2 mg/kg i.v. (control)
Number of subjects: 6
Study 31280701 — intervention group
Group type: EXPERIMENTAL
Intervention: SEGUE-based communication education (experimental group)
Number of subjects: 98
Study 31280701 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 28235524 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Fastrach intubating laryngeal mask airway (ILMA)
Number of subjects: 40
Study 28235524 — intervention group
Group type: COMPARATOR
Intervention: Flexible bronchoscopy (FB)
Number of subjects: 40
Study 28235524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 26401869 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally access hydrocelectomy (Group B)
Number of subjects: 124
Study 26401869 — intervention group
Group type: COMPARATOR
Intervention: Conventional hydrocelectomy (Jaboulay's procedure) (Group A)
Number of subjects: 124
Study 22473855 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT + TCT
Number of subjects: 60
Study 22473855 — intervention group
Group type: COMPARATOR
Intervention: TCT
Number of subjects: 60
Study 22515496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Exposure Physical Therapy
Number of subjects: 62
Study 22515496 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 62
Study 19300399 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-Based Morphometry (VBM)
Number of subjects: 21
Study 19300399 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 21
Study 17561600 — intervention group
Group type: EXPERIMENTAL
Intervention: Device closure of patent foramen ovale
Number of subjects: 1
Study 15450785 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 6 weeks
Number of subjects: 33
Study 15450785 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day) for 6 weeks
Number of subjects: 33
Study 12456439 — intervention group
Group type: EXPERIMENTAL
Intervention: Superia
Number of subjects: 14
Study 12456439 — intervention group
Group type: COMPARATOR
Intervention: Sofnolime
Number of subjects: 14
Study 10631415 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient controlled epidural analgesia with pethidine (15 mg of a 0.25% solution and a 10 minute lockout period)
Number of subjects: 78
Study 10631415 — intervention group
Group type: COMPARATOR
Intervention: Single bolus of epidural morphine 4 mg
Number of subjects: 78
Study 10631415 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient controlled epidural analgesia with pethidine
Number of subjects: 78
Study 8636370 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH administered sc daily at bedtime, target dose of 12 micrograms/kg x day
Number of subjects: 68
Study 8636370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 8636370 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH
Number of subjects: 68
Study 1763227 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline 2000 mg/die e.v. from two weeks before surgery to ten days after surgery, then 1000 mg/die i.m., 15 days per month for 6 months (Group A)
Number of subjects: 40
Study 1763227 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline 100 mg/die from two weeks before surgery to six months after surgery (Group B)
Number of subjects: 40
Study 6814227 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (60 to 320 mg/day)
Number of subjects: 20
Study 6814227 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 to 480 mg/day)
Number of subjects: 20
Study 6814227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3878652 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane administered at an inspired concentration of 0.5‐1.5% for 30 minutes after CPB.
Number of subjects: 20
Study 3878652 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl infusion continued during CPB (control group).
Number of subjects: 20
Study 29091471 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation (70-ml concentrated, 7.7 mmol)
Number of subjects: 9
Study 29091471 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; 0.1 mmol)
Number of subjects: 9
Study 27621189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 60% of their maximal oxygen uptake at 22°C for 40 min
Number of subjects: 10
Study 27621189 — intervention group
Group type: COMPARATOR
Intervention: Rest at 22°C for 40 min
Number of subjects: 10
Study 27621189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 60% of their maximal oxygen uptake at 31°C for 40 min
Number of subjects: 10
Study 27621189 — intervention group
Group type: COMPARATOR
Intervention: Rest at 31°C for 40 min
Number of subjects: 10
Study 27621189 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat exposure (31°C)
Number of subjects: 10
Study 24515273 — intervention group
Group type: EXPERIMENTAL
Intervention: AP301 (inhaled, single doses up to 120 mg)
Number of subjects: 48
Study 24515273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inhaled)
Number of subjects: 48
Study 22938661 — intervention group
Group type: EXPERIMENTAL
Intervention: SCys C-CCr
Number of subjects: 51
Study 22938661 — intervention group
Group type: EXPERIMENTAL
Intervention: SCr-CCr
Number of subjects: 51
Study 22938661 — intervention group
Group type: COMPARATOR
Intervention: APACHE II score
Number of subjects: 51
Study 22938661 — intervention group
Group type: COMPARATOR
Intervention: Urine volume
Number of subjects: 51
Study 20146803 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised educational intervention combining practice-based workshops and electronic support material
Number of subjects: 200
Study 20146803 — intervention group
Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 200
Study 20146803 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised educational intervention
Number of subjects: 200
Study 19028434 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific manipulation as adjunct to extension exercises
Number of subjects: 72
Study 19028434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no manipulation)
Number of subjects: 72
Study 16104911 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once daily
Number of subjects: 0
Study 14745215 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified unilateral intradural ventral rhizotomy of C1 and C2, extradural denervation of C3‐C6 posterior rami, and contralateral peripheral sectioning of the branches of the accessory nerve to the sternocleidomastoid muscle (Taira's method: group A)
Number of subjects: 82
Study 14745215 — intervention group
Group type: COMPARATOR
Intervention: Traditional Bertrand's procedure (Bertrand's method: group B)
Number of subjects: 82
Study 14745215 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified unilateral intradural ventral rhizotomy of C1 and C2 (Taira's method: group A)
Number of subjects: 82
Study 11423890 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal closure (Group A)
Number of subjects: 60
Study 11423890 — intervention group
Group type: COMPARATOR
Intervention: Non-repair of peritoneum (Group B)
Number of subjects: 60
Study 11423890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 60
Study 9025126 — intervention group
Group type: EXPERIMENTAL
Intervention: EMT‐1: 107 laypersons with basic life support (BLS) training
Number of subjects: 16
Study 9025126 — intervention group
Group type: EXPERIMENTAL
Intervention: EMT‐2: 16 emergency medical technicians (EMTs) in training
Number of subjects: 16
Study 9025126 — intervention group
Group type: EXPERIMENTAL
Intervention: PM‐1: 74 paramedics in training
Number of subjects: 16
Study 9025126 — intervention group
Group type: EXPERIMENTAL
Intervention: PM‐2: 9 certified paramedics
Number of subjects: 16
Study 9025126 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 16
Study 1792912 — intervention group
Group type: EXPERIMENTAL
Intervention: S2 regimen with intermediate-dose methotrexate (ID-MTX)
Number of subjects: 498
Study 1792912 — intervention group
Group type: EXPERIMENTAL
Intervention: S2 and H2 groups with ID-MTX
Number of subjects: 498
Study 1792912 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple intrathecal injections (TIT)
Number of subjects: 498
Study 1792912 — intervention group
Group type: EXPERIMENTAL
Intervention: 24Gy cranial irradiation (CRX)
Number of subjects: 498
Study 1792912 — intervention group
Group type: EXPERIMENTAL
Intervention: HEX group regimen
Number of subjects: 498
Study 6549837 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding at delivery
Number of subjects: 37
Study 6549837 — intervention group
Group type: COMPARATOR
Intervention: Not holding at delivery
Number of subjects: 37
Study 31313410 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide infusion (Day-A)
Number of subjects: 10
Study 31313410 — intervention group
Group type: EXPERIMENTAL
Intervention: l-NMMA infusion (Day-B)
Number of subjects: 10
Study 31313410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline) (Day-A)
Number of subjects: 10
Study 30358831 — intervention group
Group type: EXPERIMENTAL
Intervention: DP1-10 cocoa extract containing 130 mg (‐)‐epicatechin and 560 mg procyanidins
Number of subjects: 45
Study 30358831 — intervention group
Group type: EXPERIMENTAL
Intervention: DP2-10 cocoa extract containing 20 mg (‐)‐epicatechin and 540 mg procyanidins
Number of subjects: 45
Study 30358831 — intervention group
Group type: COMPARATOR
Intervention: Control capsule (flavanol-free)
Number of subjects: 45
Study 30358831 — intervention group
Group type: EXPERIMENTAL
Intervention: DP1-10 and DP2-10
Number of subjects: 45
Study 27448540 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth encouragement physical activity for 52 weeks
Number of subjects: 158
Study 27448540 — intervention group
Group type: COMPARATOR
Intervention: Health education and individual counseling
Number of subjects: 158
Study 25560690 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (Damon system)
Number of subjects: 22
Study 25560690 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets (Roth technique)
Number of subjects: 22
Study 22892745 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch (TE) sealer
Number of subjects: 45
Study 22892745 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch (SE) sealer
Number of subjects: 45
Study 22892745 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoxy resin-based (EP) sealer
Number of subjects: 45
Study 22892745 — intervention group
Group type: COMPARATOR
Intervention: Control group (not preincubated)
Number of subjects: 45
Study 19843354 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face counselling
Number of subjects: 90
Study 19843354 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling
Number of subjects: 90
Study 19843354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Number of subjects: 90
Study 17378788 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia plus epidural MgSO(4) (2%, 100 mg/h)
Number of subjects: 120
Study 17378788 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia plus intrathecal MgSO(4) (94.5 mg, 6.3%)
Number of subjects: 120
Study 17378788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal and epidural MgSO(4) combined
Number of subjects: 120
Study 17378788 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia alone (control)
Number of subjects: 120
Study 16277798 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based dietary intervention (dietary diversification, changes in food selection patterns, modifications to food processing)
Number of subjects: 281
Study 16277798 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based dietary intervention
Number of subjects: 281
Study 16277798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 281
Study 12230335 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicycle-run training
Number of subjects: 12
Study 12230335 — intervention group
Group type: COMPARATOR
Intervention: Normal training
Number of subjects: 12
Study 9505567 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) used off-label in conjunction with antibiotics
Number of subjects: 0
Study 9505567 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0
Study 8079178 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-sewn anastomosis
Number of subjects: 113
Study 8079178 — intervention group
Group type: COMPARATOR
Intervention: Stapled anastomosis
Number of subjects: 113
Study 2480741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine oxoglutarate (Cetornan)
Number of subjects: 52
Study 2480741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 785084 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐acetyldigoxin and Bencyclan (Verum)
Number of subjects: 46